Another explored inhibitor is eculizumab, an anti-C5 MoAb known for revolutionizing the therapeutic landscape of PNH, another form of complement-mediated, DAT-negative hemolytic anemia (Figure 3) (161). The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.